References
- Center for Behavioral Health Statistics. Key Substance Use and Mental Health Indicators in the United States:Results from the 2016 National Survey on Drug Use and Health. Veterans and Military Families | SAMHSA - Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2016/NSDUH-FFR1-2016.htm#sud. Accessed December 4, 2018.
- Opioid overdose. Centers for Disease Control and Prevention. https://www.cdc.gov/drugoverdose/. Published October 23, 2017. Accessed December 4, 2018.
- Drug overdose deaths in the United States, 1999 – 2016. Centers for Disease Control and Prevention. https://www.cdc.gov/nchs/products/databriefs/db294.htm. Published December 2017. Accessed December 9, 2018.
- ASHP statement on the pharmacists role in substance abuse prevention, education, and assistance. Am J Health Sys Pharm. 2016;73(9):e267–70.
- NCPO Statement on Combating the Opioid Crisis. NCPO Opioid Statement. January 2018. https://nabp.pharmacy/wp-content/uploads/2018/02/NCPO-Opioid-Statement-January-2018.pdf. Published January 31, 2018. Accessed December 6, 2018.
- Polices Adopted by the 2018 APhA House of Delegates. American Pharmacists Association. www.pharmacist.com/policy-manual. Reviewed 2014. Accessed December 6, 2018.
- Wu L-T, Ghitza U, Burns AL, Mannelli P. The opioid overdose epidemic: opportunities for pharmacists. Subst Abuse Rehabil. 2017;8:53–55.
- Doong KS, Gaccione DM, Brown TA. Community Pharmacist Involvement in Prescription Drug Monitoring Programs. AJPBLive. https://www.ajpb.com/journals/ajpb/2016/AJPB_NovDec2016/community-pharmacist-involvement-in-prescription-drug-monitoring-programs. Published November 13, 2016. Accessed December 9, 2018.
- Compton WM, Jones CM, Stein JB, Wargo EM. Promising roles for pharmacists in addressing the U.S. opioid crisis. Res Social Admin Pharm. 2019;15(8):910–916. doi:10.1016/j.sapharm.2017.12.009
- Toderika Y, Williams S. Naloxone for opioid overdose and the role of the pharmacist. Consult Pharm. 2018;33(2):98–104.
- Gao F. The essential role of pharmacists in the opioid crisis. Can Pharm J (Ott). 2017;150(3):216–217.
- American Pharmacists Association, Academy of Managed Care Pharmacy, American Society of Consultant Pharmacists, et al., Federal efforts to combat the opioid crisis: A status update on CARA and other initiatives. Statement for the record to the house energy and commerce committee hearing. https://www.pharmacist.com/sites/default/files/audience/Joint Statement for the Record on MAT to Energy and Commerce Hearing_10_25_2017.pdf. Published October 25, 2017. Published October 25, 2018. Accessed December 6, 2018.
- Barrett J. The Opioid Crisis: What Can Pharmacists Do? Pharmacy Times. https://www.pharmacytimes.com/conferences/aacp-2017/the-opioid-crisis-what-can-pharmacists-do. Published July 19, 2017. Accessed December 9, 2018.
- VIVITROL® (naltrexone for extended-release injectable suspension). ALK-VIV. https://www.vivitrol.com/content/pdfs/prescribing-information.pdf Revised December 2015. Accessed December 9, 2018.
- SUBOXONE®. https://www.suboxone.com/content/pdfs/prescribing-information.pdf Revised February 2018. Accessed December 9, 2018.
- Lafferty L, Hunter TS, Marsh WA. Knowledge, attitudes and practices of pharmacists concerning prescription drug abuse. J Psychoactive Drugs. 2006;38(3):229–232.
- Wenthur CJ, Cross BS, Vernon VP, et al. Opinions and experiences of Indiana pharmacists and student pharmacists: the need for addiction and substance abuse education in the United States. Res Social and Admin Pharm. 2013;9(1):90–100.
- Liberati A. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W–W94.
- Andrew M. A systematic review of pharmacists' attitudes toward buprenorphine and naloxone dispensing. PROSPERO 2018 CRD42018102163 Available from: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018102163
- IBM Watson Health Products. Truven Health Analytics Products. http://www.micromedexsolutions.com/home/dispatch Accessed December 9, 2018.
- Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.
- Hammick M, Dornan T, Steinert Y. Conducting a best evidence systematic review. Part 1: From idea to data coding. BEME Guide No. 13. Med Teach. 2010;32(1):3–15.
- Do V, Behar E, Turner C, Geier M, Coffin P. Acceptability of naloxone dispensing among pharmacists. J Pharm Pract. 2018. doi:10.1177/0897190018798465
- Meyerson B, Agley J, Davis A, et al. Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana 2016. Drug Alcohol Depend. 2018;188:187–192.
- Raisch DW, Fudala PJ, Saxon AJ, et al. Pharmacists’ and pharmacy technicians’ perceptions and attitudes toward dispensing buprenorphine and buprenorphine/naloxone to patients with opioid dependence. J Am Pharm Assoc. 2005;45(1):23–32.
- Rudolph S, Branham AR, Rhodes LA, Hayes H, Jr., Moose JS, Marciniak MW. Identifying barriers to dispensing naloxone: a survey of community pharmacists in North Carolina. J Am Pharm Assoc. 2018;58(4):S55–S58.
- Stewart B, Thomas RL, Tutag-Lehr V. Pharmacists’ knowledge, support, and perceived roles associated with providing naloxone in the community. Curr Pharm Teach Learn. 2018;10(8):1013–1021.
- Thompson EL, Rao PSS, Hayes C, Purtill C. Dispensing naloxone without a prescription: survey evaluation of Ohio pharmacists. J Pharm Pract. 2018. doi:10.1177/0897190018759225
- Thornton JD, Lyvers E, Scott V(G, Dwibedi N. Pharmacists readiness to provide naloxone in community pharmacies in West Virginia. J Am Pharm Assoc. 2017;57(2):S12–S18.
- Preventing the consequences of opioid overdose: Understanding naloxone access laws. Substance Abuse and Mental Health Service Administration (SAMHSA). https://www.samhsa.gov/capt/sites/default/files/resources/naloxone-access-laws-tool.pdf Published January 20, 2018. Accessed December 11, 2018.
- Saitz R, Larson MJ, LaBelle C, Richardson J, Samet J. The case for chronic disease management for addiction. J Addict Med. 2008;2(2):55–65.
- Treatment of opioid-use disorders. N Engl J Med. 2016;375:1596–1597.
- Treatment Improvement Protocol, TIP 63. Medications for Opioid Use Disorder TIP 63 TREATMENT IMPROVEMENT PROTOCOL For Healthcare and Addiction Professionals, Policymakers, Patients, and Families. https://store.samhsa.gov/shin/content/SMA18-5063FULLDOC/SMA18-5063FULLDOC.pdf. Published 2018. Accessed December 9, 2018.